ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Chronic Hepatitis B Data at EASL 2023
ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that two abstracts were accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2023, taking place in Vienna, Austria June 21 - 24, 2023.